InNexus Biotechnology CEO and Scientific Advisory Board Chairman to Present at Global Healthcare and Financial Conferences

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF.OB) (TSX VENTURE: IXS.V) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™)technology, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monaco, May 20^th, and the Henry Kunkel Society Annual Meeting in Italy, May 21^st-May 24^th.

CEO and Chairman Jeff Morhet, along with J. Donald Capra, M.D., Chairman of the InNexus Scientific Advisory Board, will provide a company overview, including information about InNexus’ unique business strategy, its DXL™ technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the conferences.

The Henry Kunkel Society was founded in 1990 with the goal of bringing together researchers with a strong interest in both immunology research and clinical aspects of immune-system mediated diseases. The Society is named for Henry G. Kunkel, M.D., who was a physician and professor at Rockefeller University in New York. Dr. Kunkel's illustrious scientific life was distinguished by the ability to delineate principles of fundamental human biology through meticulous study of patients with a variety of disorders of the immune system. Dr. Capra serves as The Henry Kunkel Society Program Committee Chair and further information may be viewed at: http://www.henrykunkelsociety.org/meetings.asp

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia, with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic, and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

InNexus Biotechnology Inc.
Jeff Morhet or J. Donald Capra, M.D., 480-862-7500